AVITA Medical Inc RCEL
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
AVITA Medical to Present at 2024 Cantor Global Healthcare Conference
-
AVITA Medical to Participate in Lake Street’s 8th Annual Best Ideas Growth (BIG8) Conference
-
AVITA Medical to Host Investor Webinar Briefing
-
AVITA Medical Reports Second Quarter Financial Results
-
AVITA Medical Names Robin VanDenburgh as SVP of U.S. Commercial Sales
-
AVITA Medical Expands Portfolio with Unique Dermal Matrix to Advance Wound Care
-
AVITA Medical to Announce Second Quarter 2024 Financial Results
-
AVITA Medical Appoints Nicole Kelsey as Chief Legal and Compliance Officer, and Corporate Secretary
Trading Information
- Previous Close Price
- $10.43
- Day Range
- $10.41–10.71
- 52-Week Range
- $7.59–18.88
- Bid/Ask
- $0.00 / $0.00
- Market Cap
- $275.23 Mil
- Volume/Avg
- 65,968 / 149,059
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 5.00
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult patients in the US with paediatric clinical trials and expanded indications in soft-tissue reconstruction and vitiligo underway. It is currently in roll-out across the approximately 136 US burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the US.
- Sector
- Healthcare
- Industry
- Medical Devices
- Stock Style Box
- Small Core
- Total Number of Employees
- 207
- Website
- https://www.avitamedical.com
Competitors
Valuation
|
Metric
|
RCEL
|
NAN
|
FPH
|
|---|---|---|---|
Price/Earnings (Normalized) | — | 70.98 | 101.56 |
Price/Book Value | 11.02 | 6.20 | 12.08 |
Price/Sales | 5.00 | 6.72 | 12.15 |
Price/Cash Flow | — | 51.38 | 49.71 |
Price/Earnings
RCEL
NAN
FPH
Financial Strength
|
Metric
|
RCEL
|
NAN
|
FPH
|
|---|---|---|---|
Quick Ratio | 4.65 | 5.25 | 0.88 |
Current Ratio | 5.29 | 6.16 | 1.83 |
Interest Coverage | −12.73 | 8.25 | 13.77 |
Quick Ratio
RCEL
NAN
FPH
Profitability
|
Metric
|
RCEL
|
NAN
|
FPH
|
|---|---|---|---|
Return on Assets (Normalized) | −52.01% | 6.94% | 11.54% |
Return on Equity (Normalized) | −99.59% | 9.11% | 15.07% |
Return on Invested Capital (Normalized) | −63.61% | 7.18% | 13.94% |
Return on Assets
RCEL
NAN
FPH
Medical Devices Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Abbott Laboratories
ABT
| Dcmbbrkk | Qvvwzhg | $196.1 Bil | |||
| Stryker Corp
SYK
| Ynhjhfwzjk | Dbjnk | $137.7 Bil | |||
| Boston Scientific Corp
BSX
| Tbkfnlt | Twcwqw | $122.3 Bil | |||
| Medtronic PLC
MDT
| Cbbnhzgg | Xhgvhjp | $114.7 Bil | |||
| Edwards Lifesciences Corp
EW
| Cfcrpqvyn | Mphstvn | $39.6 Bil | |||
| Koninklijke Philips NV ADR
PHG
| Prqrx | Tlvqz | $29.3 Bil | |||
| DexCom Inc
DXCM
| Dmkyvffgg | Llkx | $27.1 Bil | |||
| Steris PLC
STE
| Vvtqvktl | Hdvzs | $23.3 Bil | |||
| Zimmer Biomet Holdings Inc
ZBH
| Bhdlwjcn | Vnrl | $21.9 Bil | |||
| Insulet Corp
PODD
| Mwbklzppq | Dfdfb | $16.5 Bil |
United States